Tuesday May 16, 2017 0 comments
BOULDER -- Muse bio, a privately-held company leading the development of next-generation genome engineering capabilities, announced Dr. John Stuelpnagel, co-founder, first CEO and former COO of Illumina and a well-known genomics industry entrepreneur, will become chairman of Muse bio's board of directors.
In addition to Illumina, Stuelpnagel has co-founded and held senior leadership roles in several life science companies and brings extensive knowledge in building successful enterprises and commercializing disruptive technologies.
"We are honored and excited that Dr. Stuelpnagel has agreed to become Muse bio's chairman of the board," said Kevin Ness, CEO of Muse bio.
"Muse will benefit significantly from his industry knowledge, leadership and strategic vision as we build Muse bio and bring our ForgeCraft genome engineering technology to market."
"Muse bio's ForgeCraft technology will revolutionize how researchers undertake genome engineering, enabling them to make multiple, unique modifications at any location within a cell in a high throughput manner, right at their benchtop," said Stuelpnagel.
"I am impressed by Muse bio's team and excited to work with them as they bring this important, ground-breaking technology to market."